EURTAC Phase III study: Erlotinib nearly doubles progression-free survival vs. chemotherapy
Tuesday, July 5, 2011 - 09:31
in Health & Medicine
In the first phase III study to include Western lung cancer patients, first-line treatment with erlotinib (Tarceva) nearly doubled progression-free survival compared with chemotherapy, according to new research.
